On August 23, 2021 Everest Medicines (HKEX 1952.HK), a biopharmaceutical company focused on developing and commercializing transformative pharmaceutical products that address critical unmet medical needs for patients in Greater China and other parts of Asia, reported that it will report 2021 unaudited first half interim results after the closing of Hong Kong equity markets on August 30, 2021 (Press release, Everest Medicines, AUG 23, 2021, View Source [SID1234586828]). The Company will hold a live conference call at 9:00 AM on August 31, 2021, Beijing Time.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Conference Call Information

A live conference call will be hosted on August 31, 2021 at 9:00 AM Beijing Time (August 30, 2021 at 9:00 PM U.S. Eastern Time). Participants must register in advance of the conference call. Details are as follows:

Registration Link: View Source

Conference ID: 5468938

All participants must use the link provided above to complete the online registration process in advance of the conference call. Upon registering, each participant will receive dial-in number, passcode and a unique registration ID, which can be used to join the conference call.

A replay will be available shortly after the call and can be accessed by visiting the Company’s website at View Source